Table 3 Bivariate analysis of clinical characteristics, treatment, and evolution of patients with COVID-19 in the Adult Intensive Care Unit of the Hospital de Clínicas between August 2020 and August 2021. San Lorenzo. Paraguay (n = 214)
Variable | Deceased (n = 82) | Survivors (n = 132) | p-value |
|---|---|---|---|
Age > 60 | 40 (48.8) | 39 (29.5) | 0.005 |
Male sex | 51 (62.2) | 73 (55.3) | 0.321 |
Obesity | 40 (48.8) | 62 (47.0) | 0.797 |
Diabetes mellitus | 29 (35.4) | 27 (20.5) | 0.016 |
Cardiac disease | 8 (9.8) | 4 (3.0) | 0.076 |
Hypertension | 46 (56.1) | 61 (46.2) | 0.160 |
Chronic renal failure | 9 (11) | 3 (2.3) | 0.007 |
APACHE II > 20 | 22 (26.8) | 6 (4.5) | < 0.001 |
Renal injury | 31/68 (45.6) | 33/121 (27.3) | 0.011 |
Hepatic injury | 9/39 (23.1) | 5/65 (7.7) | 0.026 |
Remdesivir | 29 (35.4) | 80 (60.6) | < 0.001 |
Received remdesivir until the 8th day of illness | 13 (26.0) | 42 (32.1) | < 0.001 |
Received remdesivir after the 8th day of illness | 15 (18.5) | 37 (28.2) | |
No remdesivir | 53 (65.4) | 52 (39.7) | |
Plasma | 18 (22.0) | 30 (22.7) | 0.895 |
Tocilizumab | 5 (6.1) | 15 (11.4) | 0.198 |
MV | 81 (98.8) | 54 (40.9) | < 0.001 |
ARDS | 46 (56.8) | 66 (50.0) | 0.335 |
Norepinephrine | 80 (97.6) | 44 (33.3) | < 0.001 |
Hemodialysis | 22 (26.8) | 2 (1.5) | < 0.001 |
Intercurrent infections | 69 (84.1) | 96 (72.7) | 0.053 |